Yipin Red Invests RMB 35 Million to Accelerate Innovative Drug Pipeline Through Strategic Stake in Fendi Pharma

　　【Pharmaceutical Network | Corporate News] On the evening of May 12, ApicHope, a pediatric pharmaceutical company, announced that its wholly-owned subsidiary, Ruiao Biologics, would inject RMB 35 million of its own funds into FenDiPharma as a capital increase. The company stated that taking an equity stake in FenDiPharma would strengthen its core competitiveness in the field of innovative drugs, broaden its business scope, and enhance its sustainable development capabilities, aligning with its long-term strategic plans.
 

It is reported that FenDiPharma is dedicated to developing innovative drugs for the treatment of cancer and viral infectious diseases. As a domestic enterprise specializing in targeted protein degradation technology and molecular glue technology, the company owns the PRODED protein degradation drug development platform. This platform integrates artificial intelligence-based drug screening, proteolysis-targeting chimera (PROTAC) technology, and molecular glue technology, thereby accelerating the research, development, and market launch of blockbuster small-molecule drugs based on targeted protein degradation.
 

Currently, FenDiPharma remains in a loss-making position. In 2020, it achieved revenue of RMB 97,600 and incurred a loss of RMB 809,500. As of now, no products have been commercialized for production. Upon completion of this capital increase, RuiAo Biotech will hold a 25% equity stake in FenDiPharma.
 

Through this collaboration, ApicHope aims to leverage the PRODED protein degradation drug development platform to rapidly enter the field of novel targeted protein degradation small-molecule drugs for the treatment of cancer and viral infectious diseases, accelerate its innovative drug portfolio, and enhance its core competitiveness in the innovative drug sector.
 

ApicHope focuses on the research and development, manufacturing, and sales of pharmaceuticals, with its product portfolio centered on pediatric medicines and medications for chronic diseases. In recent years, the company has adhered to innovation-driven strategies and industrial resource integration, leveraging a multi-pronged approach of “technology + brand + capital” to drive high-quality corporate development. Through independent R&D, equity participation, and the establishment of industrial funds, ApicHope has expanded its business initiatives in first-in-class drugs and innovative projects targeting novel therapeutic targets, thereby further advancing its industrial layout in the field of innovative pharmaceuticals and strengthening its core competitiveness in its primary business areas.
 

To advance its strategic layout in the innovative drug industry, ApicHope recently resolved to invest in Alpha Technology. Through in-depth technical collaboration with Alpha Technology, ApicHope will enter the field of AI-driven innovative drug discovery, leverage AI technologies to empower drug R&D, accelerate the implementation of its innovative drug development strategy, and enhance its core competitiveness. It is reported that AI technology can be applied to multiple scenarios in drug R&D, helping to improve the efficiency and success rate of new drug development. Alpha Technology aims to address the weakness of domestic new drug R&D technical capabilities by integrating biocomputing, artificial intelligence, and original biotechnologies for new drug research and development.
 

From an industry perspective, pharmaceuticals are a sector with inelastic demand. As China’s population ages and the demand for treatments for cancer, cardiovascular diseases, diabetes, and other chronic conditions grows, the pharmaceutical industry enjoys vast potential for expansion. Under a series of policies encouraging pharmaceutical innovation, China’s pharmaceutical industry is transitioning from low-end to high-end development, shifting gradually from generic drugs to innovative drugs. “Innovative drugs will become a highly sought-after sector over the next decade, with promising market prospects.”
 

Further analysis predicts that by 2030, the market size of China’s innovative drugs is expected to exceed RMB 760 billion, with an additional growth potential of RMB 600 billion, as domestic pharmaceutical companies continue to expand their global influence. By 2040, China’s innovative drug market will continue to expand, with at least ten original blockbuster drugs approved for global launch. By 2050, China’s biopharmaceutical industry will become a significant component of the international landscape, accounting for 30% of the global market size.